Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 54, 1-7
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prognostic Impact of Comorbidity among Long-Term Breast Cancer Survivors: Results from the LACE StudyCancer Epidemiology, Biomarkers & Prevention, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Long-term toxic effects of adjuvant chemotherapy in breast cancerAnnals of Oncology, 2011
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Journal of Clinical Oncology, 2009
- Prognostic Significance of Nottingham Histologic Grade in Invasive Breast CarcinomaJournal of Clinical Oncology, 2008
- Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survivalAnnals of Oncology, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast CancerAnnals of Surgery, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Prognostic significance of blood vessel invasion in carcinoma of the breast in womenJournal of Surgical Oncology, 1977